Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Consensus Rating of “Moderate Buy” by Analysts

Marker Therapeutics, Inc. (NASDAQ:MRKR) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $10.1667.

Several equities research analysts recently weighed in on MRKR shares. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. HC Wainwright assumed coverage on shares of Marker Therapeutics in a research report on Monday, December 8th. They issued a “buy” rating and a $10.00 target price on the stock. Zacks Research lowered shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. Finally, Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd.

Institutional Trading of Marker Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Boyer Financial Services Inc. purchased a new position in Marker Therapeutics during the fourth quarter valued at $57,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics in the third quarter worth $33,000. Virtu Financial LLC bought a new position in shares of Marker Therapeutics during the third quarter valued at $25,000. Finally, Jane Street Group LLC purchased a new position in shares of Marker Therapeutics in the 2nd quarter worth about $33,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Price Performance

Shares of MRKR opened at $1.71 on Tuesday. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07. The company has a 50-day simple moving average of $1.58 and a two-hundred day simple moving average of $1.25. The firm has a market capitalization of $28.51 million, a PE ratio of -1.39 and a beta of 1.44.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. The firm had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%. Analysts expect that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.